On August 7, Halozyme Therapeutics rose 6.08% overnight, trading at $90.97/share, with turnover of $2,895.

The rally was driven by the company's Q2 earnings report, which significantly exceeded market expectations across all metrics, accompanied by a substantial upward revision of full-year guidance. Q2 adjusted EPS came in at $2.28, beating the analyst consensus estimate of $1.84 by approximately 24%, representing a 48% year-over-year increase. Revenue reached $481 million, surpassing estimates of roughly $407 million by approximately 19%, up 47.7% year-over-year.

The company simultaneously raised its full-year outlook to adjusted EPS of $8.65 to $9.00 on revenue of $1.835 billion to $1.91 billion, well above the prior guidance of $7.75 to $8.25 EPS on $1.71 billion to $1.81 billion in revenue. The updated guidance also meaningfully exceeds analyst consensus estimates of $7.94 EPS and $1.77 billion in revenue, reflecting continued royalty-driven outperformance and strong momentum across its ENHANZE portfolio.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)